BioAgilytix offers Ella™, from ProteinSimple®, a Bio-Techne® brand, as part of our extensive technology suite supporting complex biomarker work. Our scientists typically turn to Ella for multiplex biomarker analysis in cases where assay variability and antibody cross-reactivity are of particular concern. This platform standardizes sample preparation to ensure each assay is consistently and reproducibly run.
Learn More About Ella:
BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.
The Ella platform conducts immunoassay testing within a microfluidic Simple Plex™ cartridge. It automates the immunoassay by running samples in parallel through individual microfluidic channels, binding the protein of interest before washing off unbound analyte and adding a detection reagent. Each channel has three Glass Nano Reactors (GNRs) that are coated with a capture antibody so that results are produced in triplicate for each sample.
Ella uses fluorescence detection to enable measurement of low endogenous levels of proteins across a wider and more sensitive detection range. It also precisely controls volume on every assay, resulting in low, single-digit coefficients of variation (CVs).
Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.
BioAgilytix uses the Ella platform for biomarker studies involving multiplex analysis, especially those where assay variability and antibody cross-reactivity could otherwise pose issues. Because it detects each analyte in separate parallel channels, our scientists are able to uphold excellent assay reproducibility with minimal concern for inaccuracy of results due to antibody cross-reactivity.
Ella also yields quantitative data with a 4-5 log dynamic range using as little as 2.5 µL of sample volume. It enables triplicate sample testing with detection of up to four targeted protein antigens. Its use of the Simple Plex™ cartridge makes Ella a viable alternative to traditional plate-based ELISAs for rapid multiplex analysis of small sample volumes.
The Ella platform is able to deliver highly sensitive, reproducible results with low sample volumes. By automating assay runs, it eliminates manual steps for washes and reagent additions, as well as the chance of pipetting errors. This reduces assay variability while speeding analysis time.
Ella’s high sensitivity also makes it valuable for immunoassay studies where limited sample volume is available. Each Simple Plex™ assay yields three results from each microfluidic channel’s three GNRs, helping to maximize each aliquot of sample.
Top Benefits of Ella:
Biomarker Insight
BioAgilytix Founder and Board Member, Afshin Safavi, discusses parameters that can help guide decisions on whether to qualify or validate exploratory biomarker assays.
Ella is part of BioAgilytix’s extensive portfolio of bioanalytical technologies and automation systems supporting our core immunoassay services. As a world-class provider of biomarker services, we often deal with complex assay demands, and the Ella platform prepares us to address our customers’ multiplex biomarker analysis challenges effectively.
We are continuously optimizing our support for biomarker studies, and Ella equips us with an advanced tool to quickly and effectively deliver the quality results our customers require.
See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.
Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.
Platforms
Services